Search results
Showing 31 to 45 of 137 results for multiple sclerosis
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845
Awaiting development [GID-TA11333] Expected publication date: TBC
people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive impairment affects 43–70% of people...
with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Spasticity is a common symptom affecting up to 80% of...
people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced mobility is one of the most common...
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis
Register an interest in this interventional procedure NICE has been notified about the above procedure and considered it part of the In...
methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive...
Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes....
The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a...
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
In development [GID-TA11352] Expected publication date: TBC
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.